Cisplatin, vinblastine, and bleomycin combination therapy in resistant gestational trophoblastic disease

Alan N. Gordon, John J. Kavanagh, David M. Gershenson, Patton B. Saul, Larry J. Copeland, G. Allen Stringer

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Eleven patients were treated with cisplatin, vinblastine, and bleomycin (PVB) combination chemotherapy after failure of conventional triple‐agent therapy with methotrexate, dactinomycin, and cyclophosphamide for gestational trophoblastic disease. Often evaluable patients, five (50%) achieved negative titers. Sustained remission was achieved in only two patients (20%). Major hematologic toxicities and two deaths due to sepsis occurred in this group of patients. Although this combination does exhibit activity, its clinical use in the treatment of refractory trophoblastic disease is limited.

Original languageEnglish (US)
Pages (from-to)1407-1410
Number of pages4
JournalCancer
Volume58
Issue number7
DOIs
StatePublished - Oct 1 1986

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Cisplatin, vinblastine, and bleomycin combination therapy in resistant gestational trophoblastic disease'. Together they form a unique fingerprint.

Cite this